米托蒽醌（NSC-301739）用于晚期卵巢癌患者。妇科肿瘤学组的一项II期研究。
Mitoxantrone (NSC-301739) in patients with advanced ovarian carcinoma. A phase II study of the Gynecologic Oncology Group.
作者信息
Muss H B, Asbury R, Bundy B, Ehrlich C E, Graham J
出版信息
Am J Clin Oncol. 1984 Dec;7(6):737-9. doi: 10.1097/00000421-198412000-00026.
Abstract
Twenty-six evaluable patients with advanced epithelial ovarian cancer were treated with mitoxantrone at a dosage of 12 mg/m2 every three weeks. One patient had a partial response; four, stable disease; the remainder progressed. Mitoxantrone used in this dosage and schedule has minimal activity in patients with previously treated epithelial ovarian cancer.
摘要
26例可评估的晚期上皮性卵巢癌患者接受了米托蒽醌治疗，剂量为每三周12mg/m²。1例患者部分缓解；4例病情稳定；其余患者病情进展。以该剂量和疗程使用的米托蒽醌对既往接受过治疗的上皮性卵巢癌患者活性极小。
相似文献
1
Mitoxantrone (NSC-301739) in patients with advanced ovarian carcinoma. A phase II study of the Gynecologic Oncology Group.米托蒽醌（NSC-301739）用于晚期卵巢癌患者。妇科肿瘤学组的一项II期研究。
Am J Clin Oncol. 1984 Dec;7(6):737-9. doi: 10.1097/00000421-198412000-00026.
2
Mitoxantrone in epithelial carcinoma of the ovary. A Southwest Oncology Group study.米托蒽醌治疗卵巢上皮癌。西南肿瘤协作组的一项研究。
Am J Clin Oncol. 1984 Oct;7(5):499-501. doi: 10.1097/00000421-198410000-00020.
3
Mitoxantrone (NSC 301739) in patients with advanced cervical carcinoma. A phase II study of the Gynecologic Oncology Group.米托蒽醌（NSC 301739）用于晚期宫颈癌患者。妇科肿瘤学组的一项II期研究。
Am J Clin Oncol. 1985 Aug;8(4):312-5. doi: 10.1097/00000421-198508000-00007.
4
Southwest Oncology Group study of Mitoxantrone for treatment of patients with advanced squamous cell carcinoma of the head and neck.西南肿瘤协作组关于米托蒽醌治疗晚期头颈部鳞状细胞癌患者的研究。
Invest New Drugs. 1984;2(4):405-7. doi: 10.1007/BF00171594.
5
Phase II trial of mitoxantrone in multiple myeloma: a Southwest Oncology Group Study.
Cancer Treat Rep. 1985 Nov;69(11):1321-3.
6
Mitoxantrone: modest activity in a phase II trial in advanced prostate cancer.米托蒽醌：在晚期前列腺癌的II期试验中有适度活性。
Cancer Treat Rep. 1983 Dec;67(12):1133-5.
7
A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma.二羟基蒽二酮（DHAD，米托蒽醌，NSC 301739）用于晚期恶性黑色素瘤的II期研究。
Invest New Drugs. 1986;4(1):53-6. doi: 10.1007/BF00172017.
8
Phase I study of mitoxantrone on a daily X 5 schedule.米托蒽醌每日一次共5天给药方案的I期研究。
Am J Clin Oncol. 1984 Oct;7(5):567-70. doi: 10.1097/00000421-198410000-00035.
9
Mitoxantrone in advanced bladder carcinoma. A phase II study of the EORTC Genito-urinary Tract Cancer Cooperative Group.米托蒽醌治疗晚期膀胱癌。欧洲癌症研究与治疗组织泌尿生殖系统癌症合作组的一项II期研究。
Eur J Cancer Clin Oncol. 1985 Sep;21(9):1013-4. doi: 10.1016/0277-5379(85)90284-6.
10
Phase II studies of mitoxantrone in patients with primary liver cancer.米托蒽醌用于原发性肝癌患者的II期研究。
Invest New Drugs. 1985;3(2):187-9. doi: 10.1007/BF00174168.
引用本文的文献
1
Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials.卵巢癌化疗II期研究中患者的反应：对患者治疗及II期试验设计的启示
Br J Cancer. 1989 Apr;59(4):650-3. doi: 10.1038/bjc.1989.132.
2
Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.米托蒽醌。对其药效学和药代动力学特性以及在癌症化疗中的治疗潜力的综述。
Drugs. 1991 Mar;41(3):400-49. doi: 10.2165/00003495-199141030-00007.
Zotero 插件